Puma Biotechnology
Los Angeles
About Puma Biotechnology
Puma Biotechnology, Inc., is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of various forms of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. The Company is initially focused on the development of PB-272 (oral neratinib), a potent irreversible tyrosine kinase inhibitor, for the treatment of patients with HER2 positive metastatic breast cancer.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $100K – $500K
- Total funding: $809.3M
- Funding stage: IPO
- Last round: Post-IPO Equity (Mar 2022)
- Ticker: nasdaq:PBYI
- Website: pumabiotechnology.com
- Phone: 310-443-4150
Industries & Categories
Biotechnology, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/puma-biotechnology-63805 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.